Court upholds injunction against Apotex's generic Plavix

By Elaine Rigoli

Tampa, Fla., Sept. 21 - Sanofi-Aventis SA and Bristol-Myers Squibb Co. said the U.S. Court of Appeals for the Federal Circuit has denied the motion by Apotex to stay the Aug. 31 preliminary injunction issued by the U.S. District Court for the Southern District of New York.

That injunction ordered Apotex to halt its sales of a generic version of clopidogrel bisulfate that competes with Plavix, an antiplatelet agent developed by Sanofi-Aventis and marketed in the United States by Bristol-Myers Squibb.

Apotex had sought the stay pending its appeal of the preliminary injunction.

The Court of Appeals for the Federal Circuit has set an expedited schedule for Apotex's appeal of the preliminary injunction, with oral argument scheduled for Oct. 31.

Sanofi-Aventis is a pharmaceutical company based in Paris.

Bristol-Myers Squibb is a health-care company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.